- A global HR leader will spearhead ITM’s long-term human resources strategy, facilitating organizational development and corporate expansion
Garching / Munich, Germany, October 13, 2025 – ITM, a prominent radiopharmaceutical biotech firm, today disclosed the appointment of Annette Breunig as its Chief People Officer (CPO). Ms. Breunig possesses more than 25 years of HR leadership expertise, garnered from international pharmaceutical, manufacturing, and technology companies such as Siemens AG (FRA: SIE) and Sanofi (Nasdaq: SNY). In her role at ITM, Ms. Breunig will guide the HR team in formulating strategies designed to unite the organization, accomplish both team and business growth goals, while simultaneously empowering staff, enhancing corporate culture, and drawing in premier talent.
“Annette’s commitment to fostering high-achieving teams within global, rapidly expanding companies has cultivated vibrant work settings. As ITM progresses in expanding its operations to address the requirements of cancer patients, her leadership will be a valuable asset,” stated Dr. Andrew Cavey, CEO of ITM. “Our personnel are fundamental to our achievements. This appointment further reinforces our HR team’s capacity to uplift employees and guarantees ITM continues to be an excellent workplace as we pursue our objective of developing groundbreaking radiopharmaceuticals.”
As Executive Vice President of People & Culture at Infios Group (previously Körber Supply Chain Software), Annette spearheaded the amalgamation of the company’s staff across 10 nations in Asia, Europe, and the United States into a coherent and unified global culture. During her tenure as Vice President of HR at Körber Supply Chain Group and Körber Pharma, she founded global HR Teams, formulated and executed the companies’ worldwide people strategies, and initiated significant global culture programs. Annette also occupied global senior leadership and management capacities for over a decade at Siemens AG, where she supervised strategic and operational HR responsibilities, including the creation of systems for recruiting and nurturing elite talent, and devised compensation strategies and policies. Furthermore, she served in senior management HR positions at Aventis, which Sanofi acquired in 2004, where she developed and implemented benefit schemes across the EU, US, and Asia. Ms. Breunig is a certified business coach and possesses a business degree from Julius Maximilians University in Wuerzburg, Germany.
“ITM’s progression into a worldwide radiopharmaceutical frontrunner represents an authentic growth narrative, fueled by innovation and the dedication of its workforce. I was attracted to ITM’s distinct objective of enhancing results for cancer patients, and I eagerly anticipate collaborating with this energetic team to bolster its ongoing expansion and international triumphs,” commented Annette Breunig, CPO of ITM.
About ITM Isotope Technologies Munich SE
ITM, a prominent radiopharmaceutical biotechnology firm, is committed to delivering a novel class of radiopharmaceutical treatments and diagnostic tools for challenging-to-treat tumors. Our goal is to address the requirements of cancer patients, medical practitioners, and our collaborators through superior development, manufacturing, and global provision of medical radioisotopes. With enhanced patient benefit as the fundamental ethos guiding all our endeavors, ITM advances an extensive precision oncology pipeline, encompassing numerous Phase 3 investigations, integrating the company’s premium radioisotopes with diverse targeting molecules. By capitalizing on our two decades of trailblazing radiopharma proficiency, pivotal industry standing, and established international infrastructure, ITM endeavors to offer patients more potent targeted therapies to ameliorate clinical results and elevate quality of life.
ITM Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Telephone: +49 89 329 8986 1500
Email:
Investor Relations
Ben Orzelek
Telephone: +49 89 329 8986 1009
Email:
Attachments
